SUTIMCo signs agreement for biodetector

SUTIMCo, a subsidiary of AquaStar Holdings, Inc., has signed a venture acceleration agreement valued at $2,790,000 with Capwave Sensor, Inc., to assist in the development and commercialization of an antibody-based testing system.

Capwave created the portable Enzyme-Linked ImmunoSorbent Assay test platform, which has the ability to test for bioweapons like bacillus globigii and anthrax, toxins like salmonella and E. coli, and diseases and contaminants like bacteria and viruses.

The ability to detect pathogens may have many applications. In particular, 48 million people get sick from foodborne illnesses each year in the United States and the ability to detect the pathogens in a timely fashion might offer faster treatments, reduce hospital stays and prevent deaths.

For bioweapons testing, the product could be used by first response and armed forces teams seeking to quickly determine the toxicity of a substance.

SUTIMCo acts as a venture accelerator, offering development services to start-up companies for up to three years. The company has launched and managed businesses in health and wellness, electronic technology ventures and advanced materials. It has created high growth companies trying to take innovation from laboratory to marketplace.

"We are excited to have the opportunity to collaborate with Capwave," Malcolm Lennie, president of AquaStar Holdings, Inc., said. "It is SUTIMCo's ultimate desire to help drive transformative research that can change the world."